Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting potential growth opportunities despite recent market underperformance [2]. Core Insights - The cosmetics and medical beauty sector has underperformed the market, with the Shenwan Beauty Care Index declining by 3.1% from October 31 to November 7, 2025 [3][4]. - The upcoming Double 11 shopping festival is expected to boost performance for companies like Shuangmei Co. and Maogeping, with strong sales anticipated on platforms like Douyin and Tmall [3][9]. - Key companies such as Proya, Shanghai Jahwa, and Ruifucheng have shown varying performance, with Proya's revenue for Q3 2025 at 1.736 billion yuan, down 11.63% year-on-year, while Shanghai Jahwa's revenue increased by 28% to 1.483 billion yuan [10][16]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown a decline, with the Shenwan Cosmetics Index down 2.6%, underperforming the Shenwan A Index by 3.3 percentage points [3][4]. - The top-performing stocks this week included *ST Meigu (+12.3%) and Jinsong New Materials (+6.2%), while Huaxi Biological and Beitaini saw declines of 7.8% and 7.4%, respectively [5]. Company Performance - Proya's Q3 2025 revenue was 1.736 billion yuan, a decrease of 11.63% year-on-year, with a net profit of 227 million yuan, down 23.64% [10][11]. - Shanghai Jahwa reported Q3 revenue of 1.483 billion yuan, up 28%, with a net profit of 140 million yuan [16]. - Ruifucheng's Q3 revenue reached 819 million yuan, a significant increase of 123.4% year-on-year, with a net profit of 33 million yuan [20]. Market Trends - The 8th China International Import Expo showcased international beauty brands, indicating a shift towards high-end markets and functional skincare products [31]. - The report highlights the increasing importance of e-commerce channels, with brands like Maogeping and Shuangmei Co. performing well on platforms like Tmall and Douyin [9][24]. E-commerce Data - In September 2025, the GMV for domestic brands on Douyin and Tmall showed significant growth, with Shuangmei Co. achieving a GMV of 8.1 billion yuan, up 47% year-on-year [24]. - The overall retail sales of cosmetics in September 2025 reached 368 billion yuan, reflecting an 8.6% year-on-year growth, driven by pre-Double 11 promotions [25][27].

1. Report Industry Investment Rating - The industry rating is "Bullish" [1] 2. Core Views of the Report - The cosmetics industry continues to show differentiation, with brand demand being weak in the off - season, agents seeking change in difficult situations, and producers seizing supply - chain reconstruction opportunities. The medical aesthetics industry has new entrants with better - than - expected shipments, and new product catalysts are worth attention [3][4] 3. Summaries According to Relevant Catalogs 3.1 Cosmetics: Continued Differentiation 3.1.1 Brand Merchants - In 1 - 3Q25, beauty brand merchants' revenue was 28.4 billion yuan, a year - on - year decrease of 0.6%; personal care brand merchants' revenue was 5.7 billion yuan, a year - on - year increase of 12.4%. In 3Q25, beauty and personal care brand merchants' revenues were 8.05 billion and 1.805 billion yuan, a year - on - year decrease of 1.3% and an increase of 7.6% respectively. Beauty revenue weakened quarter - on - quarter, while personal care remained flat [18] - Beauty: Affected by the earlier Double Eleven promotion, consumer enthusiasm declined in September, and brands reduced live - streaming activities. In terms of single - quarter revenue growth, Shuiyang Co., Ltd. and Shanghai Jahwa increased by over 20%, Marubi Co., Ltd. had double - digit growth, Proya had low - double - digit decline, and Betaine and Freda had high - single - digit decline [18] - Personal care: Runben Co., Ltd.'s Q3 revenue increased by 17% year - on - year, with a slight increase in growth rate quarter - on - quarter. Baiya Co., Ltd.'s 3Q25 revenue improved, and Dengkang Oral Care had steady growth [18] - In 1 - 3Q25, beauty brand merchants' net profit after non - recurring items was 2.33 billion yuan, a year - on - year decrease of 15%; personal care brand merchants' was 604 million yuan, a year - on - year decrease of 3.4%. Some companies showed initial cost - control effects [24] 3.1.2 Agents - Agents are seeking change in difficult situations by exploring three paths: incubating self - owned brands (represented by Ruoyuchen), using AI to reduce costs and increase efficiency (represented by Yiwow), and expanding high - growth categories (such as Qingmu Technology expanding into trendy toy agency operations) [30] - Ruoyuchen's self - owned brands Feicui and Zhanjia continued to gain momentum. In Q3, self - owned brand revenue was 451 million yuan, a year - on - year increase of 344.5%, accounting for 55.1%. Zhanjia's Q3 revenue was 227 million yuan, a year - on - year increase of 119%, and 1 - 3Q revenue was 680 million yuan. Feicui's Q3 revenue was 203 million yuan, a quarter - on - quarter increase of over 98.8%, and 1 - 3Q revenue was 362 million yuan [30] 3.1.3 Producers - Demand continued to recover, and the revenue of the producer sector increased by 9%, 17%, and 30% year - on - year from Q1 to Q3, with the growth rate increasing quarter by quarter [33] - QingSong Co., Ltd. focused on optimizing customers and product structure, and its profit turned positive for four consecutive quarters from 2Q24 to 1Q25. Jieya Co., Ltd. had increasing orders from overseas big customers, and its Q3 performance growth accelerated. Jiaheng Home Co., Ltd. increased revenue but not profit, mainly due to the short - term impact of the Huzhou base's capacity ramp - up [33] 3.2 Medical Aesthetics: New Entrants with Better - than - Expected Shipments 3.2.1 Upstream Consumables - The growth rate of demand expansion slowed down, and supply - side competition intensified. In terms of the cumulative number of Class III medical device approvals, hyaluronic acid > regenerative (Sculptra/Poly - L - Lactic Acid) > botulinum toxin > recombinant collagen. Old products of hyaluronic acid and regenerative types faced growth pressure, and the growth rate of recombinant collagen Class III medical device products slowed down significantly quarter - on - quarter [38] - Hyaluronic acid: Aimeike's revenue growth rate from 24Q1 to 25Q3 was + 28.2%/+2.3%/+1.1%/ - 7%/ - 18%/ - 25%/ - 21% year - on - year, showing a quarterly decline since 24Q2 [38] - Collagen: Jinbo Biotech's revenue growth rate from 24Q1 to 25Q1 was + 76%/+100%/+92%/+73%/+63% year - on - year, and in 2Q25/3Q25, it was + 30%/+13% year - on - year. On October 23, the "Recombinant Type I α1 Subtype Collagen Freeze - Dried Fiber" Class III medical device certificate of Giant Biogene was approved by NMPA [38] - Leapmed Medical's medical aesthetics shipments were better than expected, with Q3 medical service and health management business revenue of 320 million yuan, a year - on - year increase of 28%, and the revenue of Sculptra and Hydrodermabrasion reaching 86.1367 million yuan [36] 3.2.2 Downstream - The new model of Xinoxygen Medical Clinics showed high - growth potential. The Q3 revenue guidance was 150 - 170 million yuan, a year - on - year increase of 231% - 275%, and a quarter - on - quarter increase of 4% - 18%. It plans to implement the "100 - City, 1000 - Store" plan in the long term [40] - Stores are expanding from first - tier cities to new first - tier and second - tier cities. As of November 6, it covered 42 stores in 10 cities. The promotion of self - owned brands was remarkable, and it cooperated with Xihong Miracle Sculptra 3.0, priced at 2999 yuan, which was officially launched on September 25 [43] 3.3 Investment Recommendations - Brands with upward potential and both growth and certainty: Recommend Maogeping (Oriental aesthetics, dual - wheel drive of makeup and skincare, and the second - curve of perfume is worth looking forward to) and Shangmei Co., Ltd. (with one cornerstone brand, five growth brands, and N seed businesses) [8][46] - Companies with new product pipelines and expected performance elasticity: Pay attention to Giant Biogene and Leapmed Medical [8][46] - Companies in strategic adjustment and expected to reach an inflection point: Recommend Shuiyang Co., Ltd. (the effect of high - end transformation is gradually emerging), and pay attention to Shanghai Jahwa, Betaine, and Freda [8][46]

Market Overview - The cosmetics sector experienced a decline of 1.21% on November 6, with Betaini leading the drop [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Individual Stock Performance - Notable gainers included: - Shuiyang Co., Ltd. (300740) with a closing price of 20.83, up 1.46% [1] - Qingsong Co., Ltd. (300132) with a closing price of 7.27, up 1.11% [1] - Significant decliners included: - Betaini (300957) with a closing price of 42.22, down 4.89% [2] - Jiahen Home Care (300955) with a closing price of 36.68, down 3.47% [2] Trading Volume and Capital Flow - The cosmetics sector saw a net outflow of 82.6352 million yuan from institutional investors, while retail investors had a net inflow of 58.2199 million yuan [2] - The trading volume for Shuiyang Co., Ltd. was 149,100 shares, with a transaction value of 311 million yuan [1] Capital Flow Analysis - Major net inflows were observed in: - Shuiyang Co., Ltd. with a net inflow of 23.1839 million yuan [3] - Qingsong Co., Ltd. with a net inflow of 7.1227 million yuan [3] - Major net outflows were noted in: - Betaini with a net outflow of 90.237 million yuan [3] - Shanghai Jahwa (600315) with a net outflow of 90.237 million yuan [3]

Core Viewpoint - Shanghai Jahwa's stock price has experienced fluctuations, with a year-to-date increase of 41.13% but a recent decline in the last five and twenty trading days [1] Group 1: Stock Performance - On November 6, Shanghai Jahwa's stock fell by 2.02%, trading at 23.81 CNY per share with a total market capitalization of 16.006 billion CNY [1] - The stock has seen a net outflow of 2.7626 million CNY from main funds, with significant selling pressure in large orders [1] - Year-to-date, the stock has risen by 41.13%, but it has decreased by 3.91% in the last five trading days and 4.99% in the last twenty days [1] Group 2: Company Overview - Shanghai Jahwa, established on December 1, 1995, and listed on March 15, 2001, specializes in the research, production, and sales of skincare, personal care, and maternal and infant products [2] - The company's revenue composition includes personal care (45.70%), beauty (21.48%), overseas sales (20.20%), innovation (12.55%), and other segments [2] - As of September 30, 2025, the company reported a revenue of 4.961 billion CNY, a year-on-year increase of 10.83%, and a net profit of 405 million CNY, reflecting a significant growth of 149.12% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 21.58% to 29,600, while the average circulating shares per person increased by 27.52% to 22,704 shares [2] - The company has distributed a total of 3.595 billion CNY in dividends since its A-share listing, with 344 million CNY distributed in the last three years [3] - Hong Kong Central Clearing Limited is the second-largest circulating shareholder, increasing its holdings by 3.7706 million shares [3]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][32]. Core Insights - The report highlights the recent tax policy changes regarding gold, which exempts value-added tax for standard gold transactions, potentially boosting market activity [3][22]. - The beauty care sector shows mixed performance, with some companies reporting significant revenue growth while others face declines [4][25]. - The report emphasizes the importance of domestic brands in the beauty market, with notable rankings in the Douyin beauty list indicating a shift towards local products [22][23]. Market Performance - During the week of October 27 to October 31, 2025, the retail trade, social services, and beauty care sectors experienced changes of +1.63%, +0.45%, and -2.21% respectively, ranking 8th, 17th, and 30th among 31 primary industries [13][15]. - The cosmetics sector faced a decline of -2.57%, while segments like trade and e-commerce performed well with increases of +3.44% and +2.97% [15][18]. Key Company Announcements - Shanghai Jahwa reported a revenue of 4.961 billion yuan for the first three quarters of 2025, a year-on-year increase of 10.8%, with a net profit growth of 149.1% [25]. - Proya Cosmetics achieved a revenue of 7.098 billion yuan, reflecting a modest growth of 1.89% [25]. - The opening of Pop Mart's first store in the Middle East marks a significant expansion for the brand [29]. Investment Recommendations - The report suggests focusing on companies such as Shiseido, Giant Bio, Marubi, Runben, Proya, Chaohongji, and Furuida as potential investment targets within the recommended sectors [5][32].

Group 1: Industry Overview - The cosmetics retail sales in China grew by 3.9% year-on-year from January to September 2025, slightly underperforming the overall retail market by 0.6 percentage points, indicating a stable demand environment [4][14]. - Online platforms like Tmall and Douyin are experiencing a shift, with Tmall showing signs of recovery due to flash sales and member subsidies, while Douyin's growth has slightly slowed down [17][20]. - The demand for high-end and cost-effective products is increasing, while the mid-range segment is facing pressure due to a more conservative consumer environment [5][41]. Group 2: Competitive Landscape - The trend of domestic brands replacing foreign ones is slowing down, with leading foreign brands like L'Oréal and Estée Lauder showing signs of recovery in the Chinese market [23][24]. - The growth of domestic brands is becoming more differentiated, with some brands like Proya and Shiseido experiencing declines, while others like Youngor and Shanghai Jahwa continue to grow [23][24]. - The industry is witnessing an acceleration in the multi-brand matrix among leading companies, which is expected to increase market concentration [27][28]. Group 3: Key Companies - The report highlights several companies with strong growth potential, including Ruya Chen, Shumei Co., and Maogeping, which are expected to benefit from their brand strength and market positioning [3][54]. - Companies like Dekang Oral Care and Shanghai Jahwa are noted for their stable fundamentals and potential for marginal improvement, while others like Jinbo Biological and Huaxi Biological are anticipated to reach turning points [54]. - Ruya Chen's self-owned brand, Zhenjia, has shown significant growth, with a revenue increase of 345% year-on-year in Q3 2025, indicating strong brand development capabilities [60].

Core Viewpoint - The cosmetics sector experienced a decline of 1.75% on November 4, with Marubi Biotechnology leading the drop [1][2] Group 1: Market Performance - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the cosmetics sector showed varied performance, with Qing Song Co. slightly up by 0.28% and Marubi Biotechnology down by 3.92% [1][2] Group 2: Trading Volume and Value - The trading volume and value for key stocks in the cosmetics sector were significant, with Qingdao Kingway recording a trading volume of 576,600 shares and a transaction value of 470 million yuan [2] - The total net outflow of main funds in the cosmetics sector was 208 million yuan, while retail investors saw a net inflow of 155 million yuan [2] Group 3: Fund Flow Analysis - The main funds showed a net outflow in several companies, including Marubi Biotechnology with a net outflow of 7.54 million yuan, while retail investors had a net inflow of 17.24 million yuan [3] - LaFang Co. had a net inflow of 8.17 million yuan from retail investors, despite a net outflow from main funds [3]

Core Viewpoint - The article discusses the launch of Shanghai Jahwa's "Chinese Root Beauty System" as a significant milestone in the Chinese cosmetics industry, marking a shift from ingredient competition to innovative concepts in skincare [6][25][31]. Group 1: Background and Context - The cosmetics industry has historically been dominated by Western scientific principles, leaving "Chinese skincare" underrepresented despite China's rich herbal culture and traditional medicine [4][6]. - Shanghai Jahwa released the first "Chinese Root Beauty White Paper" in September 2025, aiming to establish a systematic theoretical framework for Chinese skincare [4][5]. Group 2: The Chinese Root Beauty System - The white paper introduces the "Chinese Root Beauty System," which integrates traditional Chinese philosophy with modern skin science, proposing a comprehensive framework for skincare [8][19]. - The system redefines beauty as a reflection of overall bodily health, emphasizing the importance of internal balance and vitality over superficial treatments [8][19]. Group 3: Methodology and Principles - The system is based on a four-step cycle: Purify, Balance, Nourish, and Strengthen, which aligns with traditional Chinese medicine's holistic approach [9][10][26]. - Each step addresses different aspects of skin health, from detoxification to nourishment, creating a dynamic and sustainable skincare routine [9][10][26]. Group 4: Scientific Validation and Cultural Significance - The white paper has been positively received by experts, who recognize its scientific rigor and cultural depth, bridging traditional Chinese medicine with modern consumer understanding [14][18][23]. - The framework not only preserves traditional wisdom but also adapts it to contemporary skincare needs, establishing a credible and replicable model for the industry [14][18][23]. Group 5: Market Implications and Future Directions - The introduction of the "Chinese Root Beauty System" signifies a paradigm shift in the cosmetics industry, moving towards a more philosophical and systematic approach to skincare [25][31]. - This innovation positions Shanghai Jahwa as a leader in defining Chinese skincare standards, potentially influencing the global beauty market [26][30][31].

Core Viewpoint - Shanghai Jahwa reported a significant improvement in financial performance for the first three quarters of 2025, with total revenue reaching 4.961 billion yuan, a year-on-year increase of 11%, and a net profit of 405 million yuan, up 149% compared to the previous year [1] Financial Performance - The company's gross margin increased by 7 percentage points to 61.48%, attributed to product structure optimization and changes in raw material procurement prices [2] - The net profit margin rose by 16 percentage points to 9.41%, driven by improved gross margins and increased income from investment funds and joint ventures [2] - The company implemented strategic adjustments in 2024 due to industry downturns, which have led to a steady recovery in overall performance in 2025 [2] Business Segments - Revenue from personal care, beauty, innovation, and overseas businesses in Q3 2025 grew by 14%, 272%, 5%, and decreased by 3% respectively, totaling 606 million, 354 million, 158 million, and 365 million yuan [3] - Online sales in domestic markets increased by 173%, benefiting from a low revenue base from the previous year due to strategic adjustments [3] - The company experienced volume and price increases in personal care and beauty segments, with sales volume up by 9% and 101%, and average prices up by 5% and 85% respectively [3] Brand Strategy - The company focused on developing major products and enhancing brand building, with successful new product launches and marketing efforts [4] - Key products include the second-generation mosquito repellent from Six God, which contributed to customer growth, and the launch of a new fragrance shower gel [4] - The brand "Bai Cao Ji" achieved significant market presence with its new herbal skincare product, while "Yu Ze" and "Gao Fu" targeted specific demographics with strategic endorsements [4] Profit Forecast - The company is expected to continue its strategic adjustments, with projected EPS for 2025-2027 at 0.62, 0.76, and 0.91 yuan, corresponding to PE ratios of 41, 33, and 28 times at the current stock price [5]

Group 1 - The company announced the resignation of director Mr. Deng Minghui due to retirement, effective immediately upon delivery of the resignation report to the board [1] - Mr. Deng's departure will not result in the board falling below the legal number of members and will not affect the normal operation of the board [1] - The company will proceed with the legal process to elect a new director to fill the vacancy left by Mr. Deng [1] Group 2 - Mr. Deng has fulfilled all public commitments and has completed the necessary handover procedures [1] - The company and its board expressed sincere gratitude for Mr. Deng's contributions during his tenure [1]